Skip to main content
Clinical Trials/JPRN-jRCT1031220705
JPRN-jRCT1031220705
Recruiting
Phase 3

JCOG2202: Randomized phase III trial of laparoscopic versus open distal pancreatectomy for pancreatic cancer - LAPAN study

akamura Masafumi0 sites370 target enrollmentMarch 14, 2023

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Resectable pancreatic cancer
Sponsor
akamura Masafumi
Enrollment
370
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 14, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
akamura Masafumi

Eligibility Criteria

Inclusion Criteria

  • (1\) Pancreatic tumor diagnosed by contrast\-enhanced abdominal computed tomography (CT) meeting either one of the following conditions.
  • (i) Histologically proven invasive ductal carcinoma (adenocarcinoma or adenosquamous carcinoma)
  • (ii) Cytologically proven Class IV or Class V
  • In case of the following conditions, pancreatic tumor radiologically compatible with invasive ductal carcinoma is eligible without pathological diagnosis.
  • (a) No neoadjuvant chemotherapy
  • (b) Endoscopic ultrasound\-guided tissue acquisition or endoscopic retrograde cholangiopancreatography can not be performed safely.
  • (2\) Tumor located in the body or tail of the pancreas.
  • (3\) Resectable pancreatic cancer by contrast\-enhanced CT. Patients treated with preoperative chemotherapy fulfill both (i) and (ii).
  • (i) Resectable pancreatic cancer before chemotherapy.
  • (ii) Resectable pancreatic cancer after chemotherapy.

Exclusion Criteria

  • (1\) Synchronous or metachronous (within 5 years) malignancies.
  • (2\) Infectious disease that requires systemic treatment.
  • (3\) Body temperature of 38\.0 degrees Celsius or higher.
  • (4\) During pregnancy, within 28 days of postparturition, or during lactation.
  • (5\) Severe mental disease.
  • (6\) Receiving continuous systemic corticosteroid or immunosuppressive treatment.
  • (7\) Severe comorbidities (such as heart failure, renal failure, liver failure, hemorrhagic peptic ulcer, intestinal obstruction, and poorly controlled hypertension).
  • (8\) History of unstable angina pectoris within3 weeks or myocardial infarction within 6 months before registration.
  • (9\) Interstitial pneumonia, pulmonary fibrosis, or severe emphysema diagnosed by chest X\-ray.
  • (10\) Iodide is not allowed because of allergy, renal failure, or bronchial asthma.

Outcomes

Primary Outcomes

Not specified

Similar Trials